• LinkedIn
  • Twitter
  • Pinterest
  • Vimeo
  • Skype
  • Youtube
  • Rss
  • Home
  • Events
  • Careers at CAPTIS
  • Log In / Sign In ▼
    • Log In with LinkedIn
    • Register w/out LinkedIn
    • Login w/out LinkedIn
    • Reset Lost Password
  • 🔒 MEMBER AREA ▼
    • View your profile
    • Edit your profile
    • Log out
       ☎ US Offices 1 (800) 445-1839 Toll Free | Europe/Int'l +41 22 518 2100
CAPTIS Executive Search
  • CAPTIS
  • You are a Business
    • Executive Search
    • Our Commitments
    • Other Services
    • Our Locations
    • About Us
    • Key Values
  • You are a Healthcare Executive
    • Dealing with CAPTIS
    • Candidate Contact Form
    • Login with LinkedIn
    • Create an Account
    • Log in (Existing Account)
    • WW Trade Shows
      • Medical & Pharmaceutical
      • Orthopedics
      • Spine
      • Cardiovascular
      • Diagnostics
      • Wound Care
      • Plastic & Aesthetic Surgery
      • Surgery
      • Trauma
      • Pediatric Care
    • Industry News
      • News
      • Wall Street Beat
      • Business/Financial News
      • Clinical Trials
      • Musculoskeletal News Roundup
      • Cardiovascular
      • M&A Activity
      • Food & Drug Administration (FDA)
      • Wound Care
      • Practice Management
  • CAPTIS Magazine
    • Healthcare News
    • @CaptisCorp Twitter Timeline
    • Healthcare Events
    • CAPTIS LinkedIn Timeline
    • Articles ➜
      • Recruiting
      • Personal Development
      • News
  • Make an Inquiry
  • Contact Us
    • General Contact Form
    • Healthcare Executive Contact
    • Apply for a position at CAPTIS
    • Call 1 800 445 1839
      (Cell/Mobile US & Canada Toll Free, or Skype)
    • Call +41 22 518 2100
      (Cell/Mobile Swiss Landline Switchboard, or Skype)
  • Search
  • Menu Menu

CAPTIS – Executive Search & Management Consulting

Captare. Aestimare. Eligere. Succedere.

You are a Business

You are an Executive

Want to work at CAPTIS

Learn about our services

 

 

Executive Search
Submit an inquiry

Create and/or update

your confidential profile

 

Executive’s General Information
Create an account & Add your profile

Go to our Careers page

 

 

CAPTIS Careers

Recent Healthcare News:

12/03/2020

Zymeworks gets FDA breakthrough therapy status for HER2-targeted bispecific antibody zanidatamab in patients with BTC

The FDA grants Breakthrough Therapy designation to new medicines…
12/03/2020

Moderna seeks FDA EUA for Covid-19 vaccine candidate

12/03/2020

Amgen, Takeda, UCB enrol first patient in Covid-19 global platform study

12/03/2020

SAB Biotherapeutics awarded $57.5m from BARDA and US Department of Defense for SAB-185

12/03/2020

Dr. Reddy’s and RDIF commence clinical trials for Sputnik V vaccine in India

12/03/2020

Boston Scientific signs agreement to divest BTG Specialty Pharmaceuticals business

12/03/2020

UK regulator grants EUA status for Pfizer and BioNTech’s Covid-19 mRNA vaccine

12/03/2020

Appili announces dosing of first patient in phase 3 Covid-19 trial

12/03/2020

Eli Lilly announces 650,000 additional doses of bamlanivimab purchased by US government to treat Covid-19

12/03/2020

Roche gets FDA approval of Gavreto in advanced or metastatic RET-mutant and RET fusion-positive thyroid cancers

11/30/2020

Telix Pharmaceuticals acquires Swiss-German biotechnology company TheraPharm

The acquisition of TheraPharm provides Telix with access to a…
11/30/2020

Dr. Reddy’s to acquire select anti-allergy brands from Glenmark in Russia, Ukraine, Kazakhstan and Uzbekistan

11/30/2020

Biogen and Sage Therapeutics to jointly develop therapies in depression and movement disorders

11/30/2020

EC approves Vertex’s Symkevi plus Kalydeco to treat CF in children aged 6-11 years

11/27/2020

Haoma Medica completes first-in-human trial for NaQuinate

11/27/2020

EMA validates application for Tepotinib for treatment of advanced NSCLC with METex14 skipping alterations

11/27/2020

Astellas gets Japanese approval for Evrenzo to treat anaemia of CKD in adult patients not on dialysis

11/26/2020

Celltrion completes enrolment for global phase II clinical trial with Covid-19 treatment candidate

11/26/2020

FDA defers approval of DaxibotulinumtoxinA for Injection in glabellar lines due to Covid-19 related travel restrictions

11/26/2020

EC approves Moderna’s purchase agreement for mRNA Covid-19 vaccine

Go to the Healthcare News

Recent news from your industry: Finance, M&A, Products, Companies and more…

Upcoming Events:

We Suggest:

FDA approves Roche’s Xofluza to prevent influenza following contact with infected person

0 Comments
/
11/25/2020
The regulator has approved the company’s supplemental new drug…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2020-11-25 04:31:262020-11-25 04:31:26FDA approves Roche’s Xofluza to prevent influenza following contact with infected person

Apnimed doses first patient in phase 2 trial of AD109 in obstructive sleep apnea

0 Comments
/
11/25/2020
If successful, this pharmacologic approach could substantially…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2020-11-25 04:01:582020-11-25 04:01:58Apnimed doses first patient in phase 2 trial of AD109 in obstructive sleep apnea

Health Canada clears Appili Therapeutics for new phase 3 trial to assess Avigan to prevent Covid-19

0 Comments
/
11/25/2020
Health Canada has provided a ‘No Objection Letter (NOL)’…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2020-11-25 04:01:572020-11-25 04:01:58Health Canada clears Appili Therapeutics for new phase 3 trial to assess Avigan to prevent Covid-19

City of Hope begins phase 1 clinical trial of Covid-19 vaccine candidate

0 Comments
/
11/25/2020
City of Hope will assess the investigational vaccine, dubbed…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2020-11-25 03:01:072020-11-25 03:01:07City of Hope begins phase 1 clinical trial of Covid-19 vaccine candidate

GSK begins patient dosing in phase 3 trial of RSV maternal candidate vaccine

0 Comments
/
11/24/2020
RSV is responsible for respiratory infections such as bronchiolitis…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2020-11-24 04:31:162020-11-24 04:31:16GSK begins patient dosing in phase 3 trial of RSV maternal candidate vaccine

Pfizer doses first participant in phase 3 study evaluating anti-TFPI investigational therapy

0 Comments
/
11/24/2020
BASIS is a global Phase 3, open-label, multicenter study that…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2020-11-24 04:01:162020-11-24 04:01:16Pfizer doses first participant in phase 3 study evaluating anti-TFPI investigational therapy

HiFiBiO partners with Pharmsynthez and IBCh to develop and commercialise SARS-CoV-2 neutralising antibody in Russia

0 Comments
/
11/24/2020
The partnership aims to advance HFB30132A, a SARS-CoV-2 neutralizing…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2020-11-24 04:01:152020-11-24 04:01:16HiFiBiO partners with Pharmsynthez and IBCh to develop and commercialise SARS-CoV-2 neutralising antibody in Russia

Merck to buy biopharmaceutical firm OncoImmune for $425m

0 Comments
/
11/24/2020
Under the deal, OncoImmune shareholders will be eligible to secure…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2020-11-24 00:01:162020-11-24 00:01:17Merck to buy biopharmaceutical firm OncoImmune for $425m

ADC Therapeutics secures FDA priority review for Lonca in diffuse large B-cell lymphoma

0 Comments
/
11/23/2020
The FDA has set a Prescription Drug User Fee Act (“PDUFA”)…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2020-11-23 05:01:422020-11-23 05:01:42ADC Therapeutics secures FDA priority review for Lonca in diffuse large B-cell lymphoma

AstraZeneca’s AZD1222 vaccine demonstrates promising efficacy

0 Comments
/
11/23/2020
The high-level results from an interim analysis, including 131…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2020-11-23 05:01:412020-11-23 05:01:41AstraZeneca’s AZD1222 vaccine demonstrates promising efficacy

Clear Creek Bio doses first patient in phase 2 outpatient study of Brequinar to treat Covid-19

0 Comments
/
11/23/2020
The randomized, open label, multi-center study will enroll up…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2020-11-23 05:01:412020-11-23 05:01:42Clear Creek Bio doses first patient in phase 2 outpatient study of Brequinar to treat Covid-19

Pfizer, BioNTech seek FDA EUA status for Covid-19 vaccine

0 Comments
/
11/23/2020
The companies have submitted a request to the FDA to secure FDA…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2020-11-23 02:02:212020-11-23 02:02:21Pfizer, BioNTech seek FDA EUA status for Covid-19 vaccine

Zymeworks gets EC’s orphan drug designation for zanidatamab in patients with gastric cancer

0 Comments
/
11/20/2020
“We are encouraged by the European Commission’s and European…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2020-11-20 04:01:122020-11-20 04:01:13Zymeworks gets EC’s orphan drug designation for zanidatamab in patients with gastric cancer

Novartis secures exclusive rights for potential acute respiratory distress syndrome cell therapy

0 Comments
/
11/20/2020
ARDS is an area of significant unmet need, with an approximate…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2020-11-20 02:31:092020-11-20 02:31:09Novartis secures exclusive rights for potential acute respiratory distress syndrome cell therapy

Eli Lilly, Incyte get FDA EUA status for baricitinib plus remdesivir to treat Covid-19

0 Comments
/
11/20/2020
The EUA status facilitates distribution and emergency use of…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2020-11-20 01:01:092020-11-20 01:01:10Eli Lilly, Incyte get FDA EUA status for baricitinib plus remdesivir to treat Covid-19

FDA clears expanded access IND for APT’s PhageBank therapy for Covid-19-related bacterial infections

0 Comments
/
11/19/2020
“The FDA’s decision supports our ability to provide a new…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2020-11-19 04:31:122020-11-19 04:31:12FDA clears expanded access IND for APT’s PhageBank therapy for Covid-19-related bacterial infections

Rilzabrutinib granted FDA fast track designation for treatment of immune thrombocytopenia

0 Comments
/
11/19/2020
In addition, following positive Phase 1/2 study results, a Phase…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2020-11-19 03:31:072020-11-19 03:31:07Rilzabrutinib granted FDA fast track designation for treatment of immune thrombocytopenia

Pfizer, BioNTech’s Covid-19 vaccine candidate meets all primary efficacy endpoints in phase 3 study

0 Comments
/
11/19/2020
The data analysis showed a vaccine efficacy rate of 95% in participants…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2020-11-19 02:01:262020-11-19 02:01:27Pfizer, BioNTech’s Covid-19 vaccine candidate meets all primary efficacy endpoints in phase 3 study

Bristol Myers Squibb wraps up acquisition of MyoKardia

0 Comments
/
11/18/2020
With the closing of the deal, MyoKardia now operates as a wholly-owned…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2020-11-18 04:31:352020-11-18 04:31:36Bristol Myers Squibb wraps up acquisition of MyoKardia

Cerebral Therapeutics announces enrolment of first patient in phase 2b trial in epilepsy

0 Comments
/
11/18/2020
The trial is enrolling adult epilepsy patients with temporal…
Read more
https://www.captis.com/wp-content/uploads/2017/02/004.jpg 450 900 CAPTIS https://www.captis.com/wp-content/uploads/2016/11/logo_transp_top_final.png CAPTIS2020-11-18 04:31:342020-11-18 04:31:35Cerebral Therapeutics announces enrolment of first patient in phase 2b trial in epilepsy
PreviousNext

  • Thorough Network

  • Deep Knowledge

  • Comprehensive Process

  • Ethical Approach

  • Confidentiality

  • Assessment Capacity

99%

Percentage of successful project completion

85%

Of placed executives remain with the client company 3 or more years

  • Share on Facebook
  • Share on Twitter
  • Share on WhatsApp
  • Share on Pinterest
  • Share on LinkedIn
  • Share on Tumblr
  • Share on Vk
  • Share on Reddit
  • Share by Mail

Archives

Follow CAPTIS



CAPTIS
Followon TwitterSubscribeto RSS Feed

We Recommend

Our very best and up-to-date selection of healthcare Industries' News (Products, Markets, Companies, R&D, Technology, Opportunities, Investment & Finance...).
Read at Healthcare News

CAPTIS Newsletter

Call CAPTIS

United States Offices
1 (800) 445-1839

(United States & Canada Toll Free)

Europe & International
+41 22 518 2100

© CAPTIS - Executive Search - 2017 - [email protected]
  • LinkedIn
  • Twitter
  • Pinterest
  • Vimeo
  • Skype
  • Youtube
  • Rss
  • Events
  • For Healthcare Executives
  • Legal & Privacy Notes, GDPR & Cookies Policy
  • Client Area
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OK, got itCookies Policy
Scroll to top